Imaging Post Stereotactic Radiosurgery for Vestibular Schwannomas-When Should We Scan?
Journal
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
ISSN: 1537-4505
Titre abrégé: Otol Neurotol
Pays: United States
ID NLM: 100961504
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
1
12
2020
medline:
22
4
2021
entrez:
30
11
2020
Statut:
ppublish
Résumé
To identify the optimal time for imaging following stereotactic radiosurgery (SRS) in patients with vestibular schwannomas (VS). Retrospective case series. Tertiary, university center. Patients with VS treated with SRS. Pre- and post-SRS surveillance with magnetic resonance imaging (MRI); patients should have at least two pre- and two post-SRS scans available to be included. Patient demographics, tumor size, and growth per month ratio pre- and post-SRS and time interval between serial MRI. Forty-two patients fulfilled the inclusion criteria. The average tumor size before the treatment was 16.9 mm (range, 10-28 mm) while 2 years posttreatment it was 16 mm (range, 7-25 mm) (p = 0.5). Average time of the first MRI post-SRS was 11 months (range, 5-14) with an average change in tumor size at that time of +0.53 mm (range, -5-8). Average time to second MRI was 22.3 months (range, 12-33) with an average change in tumor size at second scan of -1.14 (range, -5-2) mm (p = 0.117). The average growth/mo ratio before SRS was 0.26 mm/mo (range, 0-1), while post-SRS 0.05 mm/mo (range, -0.3-0.5) and -0.16 mm/mo (range, -18-0.25) at the time of the first and second scan, respectively (p < 0.001). Given the initial increase in size following SRS, unless clinically indicated, MRI post-SRS at less than 1 year has no clinical value. The growth per month ratio provides more meaningful values for response to treatment than tumor size measurements.
Identifiants
pubmed: 33252368
pii: 00129492-202102000-00035
doi: 10.1097/MAO.0000000000002910
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e216-e221Informations de copyright
Copyright © 2020, Otology & Neurotology, Inc.
Déclaration de conflit d'intérêts
The authors disclose no conflicts of interest.
Références
Lin D, Hegarty JL, Fischbein NJ. The prevalence of “incidental” acoustic neuroma. Arch Otolaryngol 2005; 131:241–244.
Kontorinis G, Crowther JA. Asymmetric hearing loss and tinnitus. BMJ 2014; 348:g3601.
Hoistad DL, Melnik G, Mamikoglu B, Battista R, O’Connor CA, Wiet RJ. Update on conservative management of acoustic neuroma. Otol Neurotol 2001; 22:682–685.
Smouha EE, Yoo M, Mohr K, Davis RP. Conservative management of acoustic neuroma: a meta-analysis and proposed treatment algorithm. Laryngoscope 2005; 115:450–454.
Yoshimoto Y. Systematic review of the natural history of vestibular schwannoma. J Neurosurg 2005; 103:59–63.
Nikolopoulos TP, Fortnum H, O’Donoghue GM, Baguley DM. Acoustic neuroma growth: a systematic review of the evidence. Otol Neurotol 2010; 31:478–485.
Muzevic D, Legcevic J, Splavski B, et al. Stereotactic radiotherapy for vestibular schwannoma. Cochrane Database Syst Rev 2014; 12:CD009897.
NHS Commissioning Board, NHS Commissioning Board Clinical Reference Group for Stereotactic Radiosurgery. Clinical Commissioning Policy: Vestibular Schwannoma and Other Cranial Nerve Neuromas. 2013; Available at: https://www.england.nhs.uk/wp-content/uploads/2018/07/Stereotactic-radiosurgery-radiotherapy-for-vestibular-schwannoma-and-other-cranial-nerve-neuromas.pdf (accessed May 20, 2019).
Stapleton E, Crowther JA, Locke R, Kontorinis G. Delayed vestibular schwannoma regrowth following shrinkage after stereotactic radiosurgery: implication for life-long surveillance. Otol Neurotol 2017; 38:260–263.
Fayad JN, Semaan MT, Lin J, Berliner KI, Brackmann DE. Conservative management of vestibular schwannoma: expectations based on the length of the observation period. Otol Neurotol 2014; 35:1258–1265.
Lederman G, Lowry J, Wertheim S, et al. Acoustic neuroma: potential benefits of fractionated stereotactic radiosurgery. Stereotact Funct Neurosurg 1997; 69:175–182.
Shyamal BC, Sudheer A, Papireddy B, Anil N. Long-term outcome of gamma knife radiosurgery for vestibular schwannoma. J Neurol Surg B Skull Base 2017; 75:273–278.
Tucker DW, Gogia AS, Donoho DA, et al. Long-term tumor control rates following gamma knife radiosurgery for acoustic neuroma. World Neurosurg 2019; 122:366–371.
Meijer OWM, Weijmans EJ, Knol DL, et al. Tumor-volume changes after radiosurgery for vestibular schwannoma: implications for follow-up MR Imaging Protocol. AJNR Am J Neuroradiol 2008; 29:906–910.
Nakamura H, Jokura H, Takahashi K, Boku N, Akabane A, Yoshimoto T. Serial follow-up MR imaging after gamma knife radiosurgery for vestibular schwannoma. AJNR Am J Neuroradiol 2000; 21:1540–1546.
Rueß D, Pöhlmann L, Hellerbach A, et al. Acoustic neuroma treated with stereotactic radiosurgery: follow-up of 335 patients. World Neurosurg 2018; 116:e194–e202.
Dunn IF, Bi WL, Mukundan S, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the role of imaging in the diagnosis and management of patients with vestibular schwannomas. Neurosurgery 2018; 82:E32–E34.
Miller ME, Lin H, Mastrodimos B, Cueva RA. Long-term MRI surveillance after microsurgery for vestibular schwannoma. Laryngoscope 2017; 127:2132–2138.
Carlson ML, Van Gompel JJ, Wiet RM, et al. A cross-sectional survey of the North American skull base society: current practice patterns of vestibular schwannoma evaluation and management in North America. J Neurol Surg B Skull Base 2018; 79:289–296.
Tysome JR, Moffat DA. Magnetic resonance imaging after translabyrinthine complete excision of vestibular schwannomas. J Neurol Surg B 2012; 73:121–124.
Bukoski RS, Appelbaum EN, Coelho DH. Postoperative MRI surveillance of vestibular schwannomas: is there a standard of care? Otol Neurotol 2020; 41:265–270.